A human monoclonal antibody to neutralize all four serotypes of dengue virus derived from patients at the convalescent phase of infection

Lu, Jian-Sheng; Chen, Lei; Du, Peng; Guo, Jiazheng; Wang, Xi; Jiang, Yujia; Yu, Yun-Zhou; Wang, Rong; Yang, Zhengming

doi:10.1016/j.virol.2022.09.007

Cited by 4 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of corticosteroids and intravenous immunoglobulin use for neuroinvasive WNV disease have been conducted but have not shown benefit [ 144 , 145 ]. Monoclonal antibodies are also under investigation for the treatment of many of the flaviviruses, including DENV, ZIKV, JEV, WNV and YFV, with promising in vitro data [ 146 , 147 , 148 , 149 , 150 ].…”

Section: Treatment Of Flavivirus Infectionsmentioning

confidence: 99%

Arthropod-Borne Flaviviruses in Pregnancy

et al. 2023

View full text Add to dashboard Cite

Flaviviruses are a diverse group of enveloped RNA viruses that cause significant clinical manifestations in the pregnancy and postpartum periods. This review highlights the epidemiology, pathophysiology, clinical features, diagnosis, and prevention of the key arthropod-borne flaviviruses of concern in pregnancy and the neonatal period—Zika, Dengue, Japanese encephalitis, West Nile, and Yellow fever viruses. Increased disease severity during pregnancy, risk of congenital malformations, and manifestations of postnatal infection vary widely amongst this virus family and may be quite marked. Laboratory confirmation of infection is complex, especially due to the reliance on serology for which flavivirus cross-reactivity challenges diagnostic specificity. As such, a thorough clinical history including relevant geographic exposures and prior vaccinations is paramount for accurate diagnosis. Novel vaccines are eagerly anticipated to ameliorate the impact of these flaviviruses, particularly neuroinvasive disease manifestations and congenital infection, with consideration of vaccine safety in pregnant women and children pivotal. Moving forward, the geographical spread of flaviviruses, as for other zoonoses, will be heavily influenced by climate change due to the potential expansion of vector and reservoir host habitats. Ongoing ‘One Health’ engagement across the human-animal-environment interface is critical to detect and responding to emergent flavivirus epidemics.

show abstract

Section: Treatment Of Flavivirus Infectionsmentioning

confidence: 99%

Arthropod-Borne Flaviviruses in Pregnancy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition to flaviviruses 13,14 , ADE has been observed for mAbs against influenza virus, HIV-1, and EBOV in cell culture, but not typically when tested in animal models or in clinical trials, with a few exceptions 11,13 . The risk of ADE can be reduced by engineering substitutions into the Fc region that disrupt FcγR binding, although these substitutions may also disrupt Fc effector functions that could contribute to clinical efficacy 15,16 . Thus, when selecting antibodies best suited for use as an antiviral product, it is critical to optimize binding both to the antigen and FcγRs.…”

Section: Antibodies As Therapeuticsmentioning

confidence: 99%

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Struble¹,

Rawson²,

Stantchev³

et al. 2023

Preprint

View full text Add to dashboard Cite

Viral diseases represent a major public health concern and an ever-present risk for developing into a future pandemic. Antiviral antibody therapeutics, either alone or in combination with other therapies, have emerged as valuable preventative and treatment options, including during a global emergency. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.

show abstract

“…When selecting antibodies best suited for use as an antiviral product, it is critical to optimize binding both to the antigen and FcγRs. For mAbs, the risk of ADE can be reduced through selection of a particular IgG subclass [ 27 ], modification of Fc glycans, or engineering substitutions into the Fc region that disrupt FcγR binding; however, these substitutions may also disrupt Fc effector functions that could contribute to clinical efficacy [ 28 , 29 ]. Although ADE in cell culture and animal studies was observed with antiviral specific polyclonal IGs [ 30 ], clinical ADE was not reported to our knowledge for any FDA-approved specific IG products.…”

Section: Antibodies As Therapeuticsmentioning

confidence: 99%

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

et al. 2023

View full text Add to dashboard Cite

Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.

show abstract

A human monoclonal antibody to neutralize all four serotypes of dengue virus derived from patients at the convalescent phase of infection

Cited by 4 publications

References 40 publications

Arthropod-Borne Flaviviruses in Pregnancy

Arthropod-Borne Flaviviruses in Pregnancy

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Contact Info

Product

Resources

About